Mitochondrial α‑KG import via SLC13A5 gates the tERRα subpopulation and determines completeness of epigenetic resetting during partial reprogramming

Hypothesis

The formation of the transient ERRα‑expressing (tERRα) subpopulation that drives epigenetic resetting is limited by mitochondrial export of α‑ketoglutarate (α‑KG) to the nucleus, a step that depends on the plasma‑membrane citrate transporter SLC13A5. In aged cells SLC13A5 expression falls, reducing cytosolic citrate and consequently nuclear α‑KG availability. Low nuclear α‑KG diminishes both TET‑mediated DNA demethylation and SETD1/MLL‑catalyzed H3K4me2 deposition at pluripotency promoters, thereby restricting the tERRα pool and leaving lamina‑associated domains (LADs) incompletely cleared. Restoring SLC13A5‑mediated α‑KG import should expand the tERRα fraction, accelerate H3K4me2 accumulation, and erase age‑associated methylation marks, producing a more complete rejuvenation phenotype without full dedifferentiation.

Mechanistic Rationale

1. Metabolic‑epigenetic coupling – α‑KG is a obligate cofactor for Jumonji C histone demethylases and TET enzymes. The data show that tERRα cells exhibit dynamic H3K4me2 increases at pluripotency loci, an α‑KG‑dependent process. Yet the source of nuclear α‑KG during reprogramming remains unspecified.
2. Mitochondrial citrate shuttle – Mitochondria export citrate via the SLC25A1 transporter; cytosolic citrate is cleaved by ATP‑citrate lyase (ACLY) to acetyl‑CoA and oxaloacetate, the latter being converted to α‑KG by mitochondrial aspartate aminotransferase (GOT2) and then imported into the nucleus. SLC13A5 mediates uptake of extracellular citrate, feeding this shuttle when intracellular citrate is low.
3. Age‑related decline – Aged fibroblasts display reduced SLC13A5 mRNA and protein (publicly available GTEx data show a ~40% drop in donors >60 y). Lower SLC13A5 limits cytosolic citrate, decreasing acetyl‑CoA for histone acetylation and α‑KG for demethylation, creating a metabolic bottleneck that precedes ERRα activation.
4. Stochastic chromatin noise – Epigenetic noise facilitates occasional access to pluripotency enhancers, but without sufficient α‑KG the noise cannot be stabilized into productive H3K4me2 marks, explaining why only a rare subset becomes tERRα.

Testable Predictions

• Correlation: Single‑cell RNA‑seq of fibroblasts undergoing partial reprogramming will reveal that SLC13A5 expression peaks in the tERRα cluster (ERRαhigh, Ki67low, early Oct4‑GFP+).
• Rescue: Overexpressing SLC13A5 or supplying cell‑permeable dimethyl‑α‑KG in aged fibroblasts will increase the proportion of tERRα cells (measured by ERRα immunostaining) from ~2 % to ≥8 % and raise global H3K4me2 signal at pluripotency promoters by ≥1.5‑fold (ChIP‑qPCR).
• Epigenetic outcome: Enhanced SLC13A5 activity will reduce residual methylation at age‑associated LAD CpG sites (identified by WGBS) by ≥30 % after 7‑day partial reprogramming, bringing the epigenetic age decrement closer to the theoretical maximum observed in young cells.
• Falsifiability: If SLC13A5 knockdown in young cells does not diminish tERRα frequency or H3K4me2 deposition, the hypothesis is refuted.

Experimental Design

1. Cell sources: Obtain dermal fibroblasts from donors aged 20‑30 y (young) and 60‑80 y (aged).
2. Interventions: (a) Lentiviral SLC13A5 overexpression; (b) 5 mM dimethyl‑α‑KG supplementation; (c) CRISPRi SLC13A5 knockdown controls.
3. Readouts (day 0, 3, 7): flow cytometry for ERRα/Ki67; scRNA‑seq for transcriptional state; ChIP‑seq for H3K4me2 at OCT4, SOX2, NANOG promoters; WGBS for LAD methylation; epigenetic clock (Horvath) calculation.
4. Analysis: Compare tERRα frequency, H3K4me2 enrichment, and methylation loss across conditions; use linear mixed models to account for donor variability.

Expected Impact

Confirming that mitochondrial citrate import governs the tERRα bottleneck would link a specific metabolic transporter to epigenetic resetting efficiency. It would suggest that targeting SLC13A5 or supplying membrane‑permeable α‑KG could enhance partial reprogramming outcomes, reduce heterogeneity, and overcome the persistent aging memory that currently limits rejuvenation therapies.